Hotez reportedly is denying that his NIH grant supported the project by Shi of Wuhan Institute of Virology.
The denials are false:
(1) Funding from NIH grant AI098775 is acknowledged in a research publication by research team led by Shi Zhengli of WIV (link.springer.com/content/pdf/10…)
(3) The publication was reported to the NIH by Hotez as an outcome of his NIH grant and is listed as an outcome on the NIH website (reporter.nih.gov/search/CWfo81q…).
(4) When Hotez reported the publication to the NIJ, he certified that he was providing truthful information, subject to criminal, civil, or administrative penalties (era.nih.gov/erahelp/common…).
The publication characterized rWIV1-SHC014S, an enhanced potential pandemic pathogen that efficiently replicates in human airway cells and exhibits 10,000x enhanced viral growth and 4x enhanced lethality in humanized mice (link.springer.com/content/pdf/10…; theintercept.com/document/2021/…).
• • •
Missing some Tweet in this thread? You can try to
force a refresh
"Peter Hotez..who has denounced a congressional investigation into gain-of-function research helped fund Wuhan Institute of Virology gain-of-function work"
Critic of probe into gain-of-function research helped fund Wuhan gain-of-function usrtk.org/biohazards/cri…
"While casting concerns about Wuhan’s labs as 'fringe,' Hotez has not mentioned his own connection to a project involving a laboratory-generated chimeric SARS-related coronavirus that has come under Congress’ microscope."
Hotez channelled funding from NIH grant AI098775 for research on a laboratory-generated chimeric SARS-related coronavirus in a project led by Shi Zhengli of the Wuhan Institute of Virology.
"Scientists and former congressional investigators hope that the newly elected Congress will further promote the investigation of the origin of the SARS=-CoV-2, so that the truth will be revealed to the public"
"One party is in favor of investigation, while the other is opposed..If the midterm elections change control of either chamber, Congress will investigate. It would be much better for everyone, both in terms of policy and in terms of politics to start investigation right away."
"The next Congress will have a very different view..Opposing investigation now is futile. Opposing investigation not only is bad policy, it's bad politics. It is an error for Majority to allow issues..important to the public to be captured or monopolized by the other party."
Thacker: "We need to stop thinking of this as a science problem. This is not a science problem that will be solved by scientists. This will be solved through depositions under oath and through subpoenas for documents."
Ebright: "Science is not going to shift this from a 'could have been' to a 'probably was'..The question whether..virus entered humans through an accident..of a lab..can be answered only through a forensic investigation, not through scientific speculation." washingtonpost.com/opinions/how-c…
"Gain-of-function research of concern is defined as research activities reasonably anticipated to increase a potential pandemic pathogen's transmissibility, pathogenesis, ability to overcome immune response, or ability to overcome a vaccine or drug."
"Gain-of-function research of concern involves the creation of new health threats--health threats that did not exist previously and that might not come to exist by natural means for tens, hundreds, thousands, or tens of thousands of years."
"Big Pharma has mostly abandoned antibiotics development, and 7 of the 12 companies that..brought..drug to market in the past decade went bankrupt or left the antibiotics business because of poor sales."
"A pipeline of new drugs is vital, given the implacable capacity of bacteria to mutate and adapt."
"As antibiotics companies disappear, so does their scientific expertise, said Dr. David Shlaes, a retired pharmaceutical industry scientist." Should a particularly deadly pattern of resistance develop with no drug pipeline, it could cause destruction on a hair-raising scale"
"Drug-resistant infections pose a growing threat to public health. We’re not prepared to meet it..Antimicrobials are critical tools..The problem is that we’re not developing nearly enough of them and many of the medicines we have are no longer effective."
"The problem is not..lack of success in developing new treatments. In..past decade, antibacterial drugs in clinical trials were twice as likely to move from..testing to FDA approval versus drugs for..other diseases.
Instead, the problem is a misaligned market for antimicrobials."
"The market conditions are so discouraging that most large biopharmaceutical companies have pulled out of the sector entirely. These dynamics are causing investors to vacate the sector, too."